Abeona Therapeutics (ABEO) Investor presentation summary

Commercial-stage cell and gene therapy platform

• ZEVASKYN, an FDA-approved ex-vivo autologous gene therapy for RDEB, anchors the portfolio and demonstrates durable clinical benefit from a single application.

• In-house CGMP manufacturing and regulatory expertise support a lean, scalable commercial model.

• $168.3M in cash and equivalents as of March 31, 2026, provides financial stability.

• Experienced leadership team with deep cell and gene therapy expertise.

ZEVASKYN clinical and commercial highlights

• Demonstrates transformational wound healing and pain reduction, with no treatment-related serious adverse events over 12 years of follow-up.

• Annual US revenue potential exceeds $250M, with a $4B cumulative opportunity.

• 6 activated Qualified Treatment Centers and payer coverage for 95% of commercially insured US lives.

• Cash flow positive upon treating more than 3 patients per month.

• Strong launch momentum and expanding treatment network.

RDEB disease and treatment impact

• RDEB is a rare, severe monogenic skin disease causing fragile skin, chronic wounds, and high risk of complications.

• ZEVASKYN is the first and only gene therapy using patients' own skin cells for durable wound healing in both children and adults.

• Single application covers large wound areas and provides years of healing and pain relief.